0001209191-24-001973.txt : 20240119
0001209191-24-001973.hdr.sgml : 20240119
20240119203502
ACCESSION NUMBER: 0001209191-24-001973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240119
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rouan Sarah Kathryn
CENTRAL INDEX KEY: 0001761366
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 24546892
MAIL ADDRESS:
STREET 1: 4995 BRADENTON AVENUE
STREET 2: SUITE 240
CITY: DUBLIN
STATE: OH
ZIP: 43017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-19
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001761366
Rouan Sarah Kathryn
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
1
0
0
0
1
Common Stock, par value $0.00001 per share
2024-01-19
4
M
0
30000
8.32
A
30000
D
Common Stock, par value $0.00001 per share
2024-01-19
4
S
0
30000
23.05
D
0
D
Stock Option (Right to Buy)
8.32
2024-01-19
4
M
0
30000
0.00
D
2020-07-01
2029-07-01
Common Stock
30000
25000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023.
/s/ Michael Morneau as Attorney-in-Fact
2024-01-19